Targovax strengthens 2-year survival rate in resected pancreatic cancer with TG01
(WorldNews Norway)

Oslo, Norway, 24 May 2018 - Targovax ASA (`Targovax` or `the Company`; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces the completion of the 32-patient phase I/II clinical trial evaluating TG01 in resected pancreatic cancer in combination with standard of care chemotherapy (gemcitabine). Median overall survival (mOS) for all 32 patients was 33.4 months, which is nearly six months better than the mOS of 27.6 months for gemcitabine alone reported in the recent ESPAC4 trial(1). The trial enrolled a total of 32 patients, split in two patient cohorts receiving different dosing regimens. The first cohort consists of 19...